Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Report Description
Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Advancements in research and technology has led to commercialization of easy-to-us insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems mentioned above. Moreover, these systems offer the convenience to self-administer insulin at home. An artificial pancreas is a novel concept that promises to revolutionize the entire diabetes market. The system automatically detects glucose level in patient's blood or plasma and accordingly administers the necessary dosage of insulin. Medtronic's MiniMed 670G is one such wearable artificial pancreas. The system is automated to monitor glucose levels and deliver insulin through an insulin pump attached to the system. The artificial pancreas system comprises a transmitter, sensor, and insulin pump. This helps in continuous monitoring and diabetes management at ease.
Market Dynamics
The artificial pancreas device system (APDS) market growth would be mainly driven by increasing adoption of the highly useful systems the large base of diabetes type 1 patients, further supplemented by ever increasing incidence of type 1 diabetes. According to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1 diabetics worldwide in 2015. JDRF funds research in diabetes 1 and the non-profit organization expected the first artificial pancreas to be commercialized in 2017. According to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S. Developed regions are expected to dominate the artificial pancreas device system (APDS) market size, as these regions are early adopters of disruptive technologies. With the introduction of this technology, market for insulin pens and injectors is expected to be impacted negatively.
Market Taxonomy
This report segments the global artificial pancreas device system (APDS) market on the basis of technology, distribution channel, end user and geography. On the basis of technology, the global artificial pancreas device system (APDS) market is categorized into Treat to Range/Control to Range (TTR/CTR), Treat to Target/ Control to Target (TTR/CTT) and Threshold Suspended Device Systems. On the basis of distribution channel the global artificial pancreas device system (APDS) market is segmented into e-commerce, Standalone Retail Shops and hospitals. End user of the APDS include type 1 and type 2 diabetic patients. For comprehensive understanding of market dynamics, the global artificial pancreas device system (APDS) market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.
Key features of the study:
• This report provides in-depth analysis of the artificial pancreas systems and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 - 2024, considering 2015 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global artificial pancreas device system (APDS) market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Medtronic, Medtrum, Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, and Insulet Corporation
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
• The global artificial pancreas device system (APDS) market report caters to various stakeholders in this industry, including investors, manufacturers and distributors for artificial pancreas system and components, end users, research and consulting firms, new entrants, and financial analysts
• Various strategy matrices used in analyzing the artificial pancreas device system (APDS) market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
• Global Artificial Pancreas Device System (APDS) Market, By Technology:
o Threshold Suspended Device Systems
o Treat to Range/Control to Range (TTR/CTR)
o Treat to Target/ Control to Target (TTR/CTT)
• Global Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
o E-commerce
o Standalone Retail Shops
o Hospitals
• Global Artificial Pancreas Device System (APDS) Market, By End User:
o Type 1 Diabetic Patients
o Type 2 Diabetic Patients
• Global Artificial Pancreas Device System (APDS) Market, By Geography:
o North America
U.S.
U.S. Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
U.S. Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
U.S. Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Canada
Canada Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Canada Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Canada Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
o Europe
U.K.
U.K. Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
U.K. Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
U.K. Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Germany
Germany Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Germany Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Germany Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Italy
Italy Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Italy Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Italy Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
France
France Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
France Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
France Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Spain
Spain Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Spain Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Spain Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Russia
Russia Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Russia Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Russia Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Rest of Europe
Rest of Europe Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Rest of Europe Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Rest of Europe Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
o Asia-Pacific
China
China Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
China Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
China Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
India
India Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
India Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
India Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Japan
Japan Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Japan Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Japan Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
ASEAN
ASEAN Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
ASEAN Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
ASEAN Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Australia
Australia Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Australia Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Australia Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
South Korea
South Korea Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
South Korea Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
South Korea Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Rest of Asia Pacific (APAC)
Rest of Asia Pacific Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Rest of Asia Pacific Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Rest of Asia Pacific Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
o Latin America
Brazil
Brazil Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Brazil Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Brazil Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Mexico
Mexico Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Mexico Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Mexico Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Argentina
Argentina Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Argentina Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Argentina Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Rest of Latin America
Rest of Latin America Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Rest of Latin America Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Rest of Latin America Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
o Middle East
GCC
GCC Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
GCC Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
GCC Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Israel
Israel Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Israel Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Israel Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Rest of Middle East
Rest of Middle East Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Rest of Middle East Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Rest of Middle East Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
o Africa
North Africa
North Africa Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
North Africa Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
North Africa Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
Central Africa
Central Africa Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Central Africa Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
Central Africa Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
South Africa
South Africa Artificial Pancreas Device System (APDS) Market, By Technology:
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
South Africa Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
E-commerce
Standalone Retail Shops
Hospitals
South Africa Artificial Pancreas Device System (APDS) Market, By End User:
Type 1 Diabetic Patients
Type 2 Diabetic Patients
• Company Profiles
o Medtronic*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
o Medtrum
o Tandem Diabetes Care, Inc.
o Johnson & Johnson
o Beta Bionics
o Bigfoot Biomedical
o Insulet Corporation
o Pancreum, Inc.
o TypeZero Technologies, Inc.
o DreaMed Diabetes Ltd
o Inreda Diabetic BV
"*" marked represents similar segmentation in other categories in the respective section.